Compare CVS Health Corp (CVS) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Invesco Ltd. — how do they compare? CVS Health Corp trades at $85.46 (market cap $112.29B), while Invesco Ltd. trades at $30.09 (market cap $13.28B). The key difference: CVS Health Corp is far larger — about 8.5× Invesco Ltd.'s market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Invesco Ltd. for 77 Days on average.
| CVS | IVZ | |
|---|---|---|
Market Cap | $112.29B | $13.28B |
Volume | 7,763,676 | 3,698,033 |
Sector | Health | Financials |
52-Week High | $110.60 | $33.31 |
52-Week Low | $70.08 | $22.44 |
Typical Hold Time | 83 Days | 77 Days |
Enterprise Value | $174.64B | $23.45B |
Dividend Yield | 3.03% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Invesco (IVZ) trades at $30.50, showing modest daily gains of 0.39%. The stock presents mixed signals with bearish technical indicators but positive analyst sentiment featuring 12 buy ratings and a $33.71 consensus target. Recent financials show revenue growth to $6.38B in 2025, though net income remains negative at -$281.70M. The company maintains strong operating cash flow of $1.53B and recently announced a $0.22 dividend for H2-2026.
Investment outlook balances analyst optimism against fundamental challenges. The 8.8% upside to consensus target suggests potential, but negative profitability metrics and bearish technicals warrant caution. Key catalysts include Q3 2026 earnings release on October 27 and continued AUM growth momentum, while risks center on margin pressure and market volatility affecting asset management revenues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
